All In Biotech

Free tool

FAERS Monitor: Visionblue

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021670 or its brand name (Visionblue, Trypan Blue). Reports on generic versions are filed under their own applications.

Reports

44

Serious

43

98% of reports

Hospitalization

1

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • toxic anterior segment syndrome24
  • blindness21
  • corneal oedema10
  • product quality issue6
  • cerebral infarction3
  • endophthalmitis3
  • off label use3
  • pigmentation disorder3
  • thyroid disorder3
  • condition aggravated2
  • vision blurred2
  • corneal decompensation1
  • corneal degeneration1
  • drug interaction1
  • liquid product physical issue1

Reports by year received

View as table
YearReports
20101
201421
20166
20176
20184
20191
20213
20221
20251

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,115 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
toxic anterior segment syndromeSignal2410762.98164.4242,178
corneal decompensation12990.6428.1742
corneal oedemaSignal102142.91240.819,236
corneal degeneration11985.5284.8493
blindnessSignal21246.5180.94,899
endophthalmitisSignal3239.280.2493
pigmentation disorderSignal3232.477.9479
thyroid disorderSignal393.031.2189
liquid product physical issue165.59.415
cerebral infarctionSignal358.719.7117
product quality issueSignal621.110.096
vision blurred27.01.85
condition aggravated23.10.81
drug interaction13.00.40
off label use31.60.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.